AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Jeito claimed the new bankroll, which will support 15 to 20 clinical-stage companies, is the largest ever for a “fully ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...